Last €4.40 EUR
Change Today +0.56 / 14.62%
Volume 24.8K
APS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:38 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (APS) Snapshot

Open
€3.79
Previous Close
€3.84
Day High
€4.40
Day Low
€3.71
52 Week High
09/9/13 - €16.92
52 Week Low
10/31/13 - €1.57
Market Cap
821.7M
Average Volume 10 Days
23.7K
EPS TTM
--
Shares Outstanding
186.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARIAD PHARMACEUTICALS INC (APS)

ariad pharmaceuticals inc (APS) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (APS) Details

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

307 Employees
Last Reported Date: 03/3/14
Founded in 1991

ariad pharmaceuticals inc (APS) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $749.8K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $465.4K
President of Research & Development and Chief...
Total Annual Compensation: $492.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $679.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $427.3K
Compensation as of Fiscal Year 2013.

ariad pharmaceuticals inc (APS) Key Developments

Ariad Pharmaceuticals Inc.(NasdaqGS:ARIA) added to Russell 2000 Index

Ariad Pharmaceuticals Inc. will be added to the Russell 2000 Index.

Ariad Pharmaceuticals Inc.(NasdaqGS:ARIA) dropped from Russell 1000 Index

Ariad Pharmaceuticals Inc. will be removed from the Russell 1000 Index.

ARIAD Pharmaceuticals Re-Appoints Deloitte & Touche LLP as Independent Registered Public Accounting Firm for 2014

On June 25, 2014, the stockholders of ARIAD Pharmaceuticals Inc. approved, at the company's 2014 annual meeting of stockholders the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:GR €4.40 EUR +0.56

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.88 USD +0.04
Array BioPharma Inc $4.35 USD +0.42
Evotec AG €3.91 EUR +0.179
Exelixis Inc $3.78 USD +0.19
Insys Therapeutics Inc $27.30 USD +1.48
View Industry Companies
 

Industry Analysis

APS

Industry Average

Valuation APS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.7x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit www.ariad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.